Page 4 - Pharma

Healthcare site Practo aims to double international revenue in 3 years: CEO

The company, which achieved profitability in the March 2024 quarter, was valued at $418 million as of April 2022, according to data from market intelligence platform Tracxn

Venus Remedies gets GMP renewal certification from Ukraine's SMDC

Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 .

Goyal criticises attempts to secure pharma patents via minor innovations

Commerce and Industry Minister Piyush Goyal on Sunday criticised attempts of certain firms to secure pharmaceutical patents through minor incremental innovations, stating that such practices could deprive millions from access to affordable medicines. Just for the "super-natural" profits of a few companies and their shareholders, the world has to suffer and is deprived of quality and equitable healthcare, he said. "I received requests very often that we should also allow pharmaceutical companies... to have incremental changes to their patents and allow them to have a fresh patent for another long period of time, which we normally understand that as evergreening of patents. "It is so sad that just for the profit of a few companies, just for the supernatural profits of a select few companies and possibly their shareholders, the world has to suffer," he said here at an event. Section 3(d) of the Indian Patents Act, 1970 restricts patents for already-known drugs unless the new claims ar

Threefold rise in trade restrictions since 2019: FM Nirmala Sitharaman

Speaking at the Stanford University, the FM flagged a threefold increase in trade restrictions since 2019 with both advanced and emerging economies striving to protect domestic production and jobs

CDSCO flags spurious batch of Telma, 131 other drugs fail quality tests

One of the popular hypertension medication brands Telma 40 samples were found to be spurious in raids across locations

Spurious batch of Telma H flagged, 103 other drugs fail CDSCO tests

Telma H is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

NPPA revises ceiling prices for over 900 drug formulations from April 1

With the changes, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government

US prosecutors investigate tip about timing of Pfizer's Covid vaccine

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company

Drugmakers Mallinckrodt, Endo agree to merge in nearly $7 billion deal

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion

Indian pharma market registers over 8% growth in January 2025: Pharmarack

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth

Pharma dept reprimands AbbVie Healthcare for unethical marketing practices

Company sponsored 'extravagant pleasure trips' abroad of 30 doctors, violating code on pharmaceutical marketing practices

Swiss PE eyes IT, pharma in India portfolio rejig after 300% gain

The fund is looking to exit some India investments and deploy the winnings in other sectors in the country such as healthcare, technology, education and shadow lending

Blackstone, Bain to bid for Mitsubishi pharma unit in up to $3.5 bn deal

Mitsubishi Chemical has hired Goldman Sachs to run the sale process and binding bids are due on Dec. 24, the sources said

CDMO player OneSource expands GLP-1 drug-device capacity as demand soars

OneSource Specialty Pharma recently raised Rs 801 crore through equity issuance

Six pharma companies sign MoUs with Telangana govt for Pharma City

Six prominent pharmaceutical companies, including Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have signed memorandums of understanding (MoUs) with the Telangana government to set up facilities in the Pharma City near here, the government announced on Friday. The companies have committed to invest over Rs 5,260 crore, which is expected to create 12,490 job opportunities in the pharma sector, according to an official release. Representatives from the companies met with Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Secretariat to finalise the agreements. "The pharma company managements signed MoUs to establish the industries. The six companies expressed their interest to invest more than Rs 5260 crore. The investments will provide 12,490 job opportunities in the pharma sector. The government will allocate land for the establishment of the new pharma manufacturing units in the recognised pharma city, the release said. According to the MoUs

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent

Pharmaceutical firms up their game to crackdown on spurious drugs

The concluding part of the series delves into strategies being applied by leading drug firms to battle counterfeits

Entod Pharma meets DCGI, issues clarification over eye drop 'claims'

Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops

PLI scheme: 50 units to be set up for pharma, medical device manufacturing

As many as 50 new greenfield plants are in the pipeline to come up in the next two years under the Production-linked Incentive (PLI) scheme for pharma and medical devices manufacturing, a senior government official said on Thursday. Speaking at the Annual Pharma Summit organised by industry body Assocham, Department of Pharmaceuticals Secretary Arunish Chawla said as the 'Make in India' initiative completes ten years, already 50 plants have been set up under the PLI schemes for the two sectors. "The PLI schemes in the pharma and meditech sectors have been a roaring success, 50 brand new greenfield pharma and medical device manufacturing plants have already become operational, and 50 more are in the pipeline," he said. When asked on the sidelines of the summit when the 50 new greenfield plants will come up, he said, "Everything will be completed in the next two years." Elaborating on the success of the PLI schemes, Chawla said, "In the last two years alone, the PLI plants have ...

Union health ministry approves new treatment for multi-drug resistant TB

The Union health ministry has approved the introduction of the BPaLM regimen, a novel treatment for multi-drug resistant tuberculosis (MDR-TB) under its National TB Elimination Program (NTEP) as a highly effective and shorter treatment option. This regimen includes a new anti-TB drug namely Pretomanid in combination with Bedaquiline and Linezolid (with or without Moxifloxacin), the ministry said in a statement.\ Pretomanid has earlier been approved and licensed for use in India by the Central Drugs Standard Control Organization (CDSCO). The BPaLM regimen, which consists four-drug combination -- Bedaquiline, Pretomanid, Linezolid and Moxifloxacin -- has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure, the ministry said. "While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with a high treatment success rate," the stateme